/PRNewswire/ A new study with TikoMed s lead drug candidate, ILBĀ®, addressing underlying causes of neurodegeneration in acute and chronic diseases, was.
VIKEN, Sweden, Aug. 3, 2022 /PRNewswire/ A new study with TikoMed's lead drug candidate, ILB, addressing underlying causes of neurodegeneration in acute and chronic diseases, was published